MetaVia to Showcase DA-1726 Weight-Loss and Vanoglipel Hepatic Data at Investor Forum
MTVA•MetaVia CEO Hyung Heon Kim will present on June 24 at the Life Sciences Virtual Investor Forum, highlighting its obesity drug DA-1726 and MASH candidate vanoglipel. DA-1726’s Phase 1 trial showed best-in-class weight loss, glucose control and waist reduction, while vanoglipel demonstrated direct hepatic benefits in Phase 2a.
1. Investor Presentation Details
Hyung Heon Kim, President and CEO of MetaVia, will participate in a live fireside chat on June 24 at 10:30 am ET during the Life Sciences Virtual Investor Forum. The interactive webcast allows real-time investor questions and will be archived for later viewing.
2. Obesity Therapy Candidate DA-1726
DA-1726 is a novel oxyntomodulin analogue acting as a dual GLP-1 and glucagon receptor agonist, designed to decrease food intake and boost energy expenditure. In a Phase 1 multiple ascending dose trial, it delivered best-in-class results for weight loss, glucose control and waist circumference reduction.
3. MASH Candidate vanoglipel
Vanoglipel, a first-in-class GPR119 agonist, has shown differentiated hepatic benefits including reduced steatosis, inflammation and fibrosis in preclinical studies. A Phase 2a clinical trial confirmed its direct liver-targeted action alongside glucose-lowering effects.
4. Investor Engagement
Investors are encouraged to pre-register for the virtual forum and can schedule one-on-one meetings with management for deeper discussions. Contact information is provided for arranging private meetings outside the conference schedule.
